SynAct Pharma AB (OM: SYNACT)
Health Care · Biotechnology · SE
Skr16.90
-5.06% today · -20.7% 1Y
SynAct Pharma AB (OM: SYNACT) operates in the Biotechnology industry within the Health Care sector. The company is valued at $99.32M and employs 8 people.
Over the last twelve months the share price has lost 20.7%, trading between 7.05 and 25.30.
Tweenvest scores SynAct Pharma AB across four factors: quality 36/100, value 38/100. Its strongest factor is value.
SYNACT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $99.32M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.97
- Dividend yield
- —
- Beta (5Y)
- 0.79
- 52-week high
- Skr25.30
- 52-week low
- Skr7.05
- Avg volume (3M)
- —
- Shares outstanding
- 56.00M
- Employees
- 8
- Next earnings
- —
About SynAct Pharma AB
SynAct Pharma AB, operating through its subsidiary SynAct Pharma ApS, specializes in creating pharmaceutical interventions for the acute exacerbation of inflammatory conditions. The company's primary investigational compound, AP1189, is currently being developed for the treatment of both rheumatoid arthritis and idiopathic membranous glomerulonephritis. Additionally, SynAct Pharma maintains a collaborative research initiative with the University of Örebro, focusing on the mitigation of inflammation in vascular diseases. Established in 2012, the firm's corporate headquarters are situated in Lund, Sweden.
- ISIN
- SE0008241491
- Founded
- 2012
- Listed since
- Jul 11, 2016
- Exchange
- OMX Nordic Exchange Stockholm
- Currency
- SEK
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Citius Oncology, Inc.NasdaqCM: CTOR | $100.47M | $0.84 | -12.11% |
| Cellectis S.A.ENXTPA: ALCLS | $99.91M | €1.23 | -2.07% |
| Faron Pharmaceuticals OyAIM: FARN | $99.74M | £0.37 | +5.19% |
| Pet Pharm Biotech Co., Ltd.TPEX: 7762 | $99.39M | NT$54.50 | +2.44% |
| Novogenia AGMUN: 7V0 | $98.11M | €7.20 | — |
| Y-Biologics, Inc.KOSDAQ: A338840 | $97.21M | ₩8,520.00 | +2.16% |
| Senhwa Biosciences, Inc.TPEX: 6492 | $96.53M | NT$34.40 | +0.58% |
| Medivir AB (publ)OM: MVIR | $96.31M | Skr1.55 | -2.15% |
Figures last refreshed Oct 4, 2026.